Reviva制药控股宣布Recover-2研究计划:2026年Q2启动试验活动,Q3开始患者入组

美股速递
Apr 15

根据最新SEC文件披露,Reviva Pharmaceuticals Holdings, Inc. (简称Reviva制药控股) 已正式规划其关键临床研究Recover-2的推进时间表。该公司计划于2026年第二季度启动相关试验活动,随后在第三季度正式开始患者招募工作。

这一重要进展标志着Reviva制药控股在推进其研发管线方面迈出实质性步伐。Recover-2研究的顺利开展将对公司未来发展产生深远影响,为后续临床开发奠定坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10